symp1

0

T. Hammond (Astra Zeneca PLC) (U.K.): Use of safety pharmacology data in early risk assessment.

A. Bass (Schering-Plough Research Institute) (U.K.): Assessment of cardiovascular/cardiac functions – Current status and future perspectives.

L. Kinter (U.K.): Impact of the ICH guidelines for SP on drug discovery/development.

D.J. Murphy (U.K.): Assessment of respiratory function – Current status and future perspectives.

R. Porsolt (France): Assessment of central nervous function – Current status and future perspectives.

J.P. Valentin (U.K.): Innovation and application of in vitro safety pharmacology methodologies.